Home » Stocks » INFI

Infinity Pharmaceuticals, Inc. (INFI)

Stock Price: $3.45 USD 0.02 (0.58%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 305.83M
Revenue (ttm) 1.76M
Net Income (ttm) -41.24M
Shares Out 75.73M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $3.45
Previous Close $3.43
Change ($) 0.02
Change (%) 0.58%
Day's Open 3.46
Day's Range 3.36 - 3.48
Day's Volume 815,698
52-Week Range 0.78 - 5.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CASI, ISR, PDSB, SVRA
3 weeks ago - 24/7 Wall Street

Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

Shares of Infinity Pharmaceuticals (NASDAQ:INFI) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 21.05% year over year to ($0.15), which ...

4 weeks ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially firs...

4 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

1 month ago - Business Wire

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

1 month ago - Business Wire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: NBEV, FINV, SBBP, SVRA
2 months ago - 24/7 Wall Street

Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Infinity (INFI) delivered earnings and revenue surprises of -6.25% and 11.80%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Infinity Pharmaceuticals (NASDAQ:INFI) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 15.00% over the past year to ($0.17...

2 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially firs...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company, today announced that management will present at the H.C. Wainwright Global Life ...

3 months ago - Business Wire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CVE, ASC, CHRA, VTGN
3 months ago - 24/7 Wall Street

Infinity Pharmaceuticals is my pick for Stock of the Year. And Shopify is my selection for Stock of the Decade.

Other stocks mentioned: AMZN, BMY, GILD, NVAX, RHHBY, SHOP, TRIL ...
3 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, an oral, immuno-oncology mac...

4 months ago - Business Wire

The company reported results from a clinical study.

4 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today presented data from MARIO-275 (MAcrophage Reprogramming in Immune Oncology), a random...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

4 months ago - Business Wire

Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmaceutical com...

Other stocks mentioned: BCLI, ORTX, VIVO
4 months ago - Benzinga

With the trading day about halfway over, the broad markets were trading sideways into the weekend.

Other stocks mentioned: BIIB, FTNT, KSS, PINS, ARWR, DECK, IP ...
4 months ago - 24/7 Wall Street

Does Infinity Pharmaceuticals (INFI) have what it takes to be a top stock pick for momentum investors? Let's find out.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will participate in a Fireside Chat with Andrew D'Silva of B. Riley Securities on Wednesday, January 20, 2021 at 10:30 am...

4 months ago - Business Wire

Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting data from MARIO-275 on the first day of the American Society of Clinical Oncology (ASCO) 2021 Genitour...

5 months ago - Business Wire

Infinity (INFI) provides an update on Eganelisib in patients with metastatic urothelial cancer.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this month. The ...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today provided an update on MARIO-275, the Company's randomized, placebo controlled Phase 2 study evaluating the benefit ...

5 months ago - Business Wire

Sorrento Therapeutics (NASDAQ: SRNE) shares are trading higher on Wednesday after the company announced it has received CLIA Licensure from the State of California that permits testing of clinical sampl...

Other stocks mentioned: SRNE
6 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that data from the front-line triple negative breast cancer (TNBC) cohort from the ongoing MARIO-3 clinic...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies...

6 months ago - Business Wire

Recent results pleased analysts. The company's relationship with various Big Pharma companies will be key to  future revenues and to the stock price.

6 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in triple neg...

6 months ago - Business Wire

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Infinity (INFI) delivered earnings and revenue surprises of -6.67% and 130.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2020 financial results and provided an update on the Company, including its third quart...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the presentation of data from the melanoma and squamous cell carcinoma of the head and neck (SCCHN) cohor...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class immuno-oncology product candidate that se...

7 months ago - Business Wire

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC in the fir...

8 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eganelisib (IPI-5...

8 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc.

9 months ago - Business Wire

Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Infinity (INFI) delivered earnings and revenue surprises of 20.00% and 80.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

About INFI

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the d... [Read more...]

Industry
Biotechnology
CEO
Adelene Perkins
Employees
23
Stock Exchange
NASDAQ
Ticker Symbol
INFI
Full Company Profile

Financial Performance

In 2020, INFI's revenue was $1.72 million, a decrease of -43.62% compared to the previous year's $3.05 million. Losses were -$40.49 million, -13.95% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for INFI stock is "Buy." The 12-month stock price forecast is 8.50, which is an increase of 146.38% from the latest price.

Price Target
$8.50
(146.38% upside)
Analyst Consensus: Buy